ROSALIND ADVISORS INC
Q1 2026 Form 13-F
TORONTO, ONTARIO, CANADA
CIK 0001622627
· Institutional investment manager
$248.9M Reported Value Total
Reported value
$248.9M
Quarter over quarter
-13.5%
Holdings
32
Top-10 concentration
66.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Steven Salamon
President, Rosalind Advisors, Inc.
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 14, 2026 |
| Form | 13F-HR |
| Reported value | $248.9M |
| Positions | 32 |
| Change in reported value | -12.5% |
| New positions | 11 |
| Exited positions | 8 |
| Position turnover | 47.5% |
| Top-10 concentration | 66.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
35 | $311.9M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
29 | $269.2M |
|
Q1 2026 13F
Filed May 14, 2026
|
32 | $248.9M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
29 | $284.5M |
|
Q3 2025 13F
Filed Nov 13, 2025
|
29 | $292.6M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $210.9M |
|
Q1 2025 13F
Filed May 14, 2025
|
31 | $205.6M |
|
Q4 2024 13F
Filed Feb 11, 2025
|
28 | $195.6M |
|
Q3 2024 13F
Filed Oct 30, 2024
|
29 | $156.2M |
|
Q2 2024 13F
Filed Jul 12, 2024
|
35 | $130.0M |
|
Q1 2024 13F
Filed Apr 25, 2024
|
31 | $107.0M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
27 | $121.4M |
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | DCTH DELCATH SYSTEMS, INC. | $30.6M | 12.31% |
| 2 | XERS XERIS BIOPHARMA HOLDINGS INC | $18.7M | 7.53% |
| 3 | FENC FENNEC PHARMACEUTICALS INC | $17.9M | 7.19% |
| 4 | SVRA SAVARA INC | $17.5M | 7.03% |
| 5 | PCVX VAXCYTE INC | $16.9M | 6.77% |
| 6 | EYPT EYEPOINT PHARMACEUTICALS INC | $13.4M | 5.37% |
| 7 | XFOR X4 PHARMACEUTICALS INC | $13.3M | 5.33% |
| 8 | VOR VOR BIOPHARMA INC | $12.5M | 5.02% |
| 9 | MDWD MEDIWOUND LTD | $12.1M | 4.85% |
| 10 | VSTM VERASTEM INC | $11.3M | 4.55% |
| 11 | CLDX CELLDEX THERAPEUTICS INC | $10.5M | 4.21% |
| 12 | BCRX BIOCRYST PHARMACEUTICALS INC | $8.8M | 3.53% |
| 13 | CYBN CYBIN INC | $7.4M | 2.95% |
| 14 | CGON CG ONCOLOGY INC | $6.8M | 2.72% |
| 15 | NSPR INSPIREMD INC | $6.4M | 2.56% |
| 16 | AVIR ATEA PHARMACEUTICALS INC | $6.3M | 2.53% |
| 17 | PROF PROFOUND MEDICAL CORP | $5.4M | 2.16% |
| 18 | VRDN VIRIDIAN THERAPEUTICS INC | $4.9M | 1.97% |
| 19 | REPL C REPLIMUNE GROUP INC | $2.7M | 1.1% |
| 20 | PYPD POLYPID LTD | $2.6M | 1.05% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.